Clinical Trial Update: Alpha-lipoic Acid in Patients at Risk for Paclitaxel Induced Neuropathy [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 trial evaluating alpha-lipoic acid to reduce paclitaxel-induced peripheral neuropathy risk has completed with results posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chemotherapy-induced Peripheral Neuropathy
• Peripheral Neuropathy

Drugs mentioned

• Alpha Lipoic Acid (alpha-lipoic acid)

Snippet

Sponsor: Northwestern University | Conditions: Peripheral Neuropathy | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2014-10-02